330 related articles for article (PubMed ID: 24853419)
21. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.
Qu Y; Chen Q; Lai X; Zhu C; Chen C; Zhao X; Deng R; Xu M; Yuan H; Wang Y; Yu J; Huang J
Mol Cancer; 2014 Apr; 13():95. PubMed ID: 24775912
[TBL] [Abstract][Full Text] [Related]
22. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
23. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
Kiel C; Serrano L
Sci Signal; 2009 Jul; 2(81):ra38. PubMed ID: 19638615
[TBL] [Abstract][Full Text] [Related]
24. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
25. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract][Full Text] [Related]
26. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
Mackenzie GG; Bartels LE; Xie G; Papayannis I; Alston N; Vrankova K; Ouyang N; Rigas B
Neoplasia; 2013 Oct; 15(10):1184-95. PubMed ID: 24204197
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
28. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
29. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Shankar S; Srivastava RK
PLoS One; 2014; 9(4):e92161. PubMed ID: 24694877
[TBL] [Abstract][Full Text] [Related]
30. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
32. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
33. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
Mazumdar T; Sen B; Wang Y; Peng S; Nicholas C; Glisson BS; Myers JN; Johnson FM
Anticancer Drugs; 2015 Sep; 26(8):835-42. PubMed ID: 26053277
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
36. Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway.
Lechuga CG; Simón-Carrasco L; Jacob HK; Drosten M
Methods Mol Biol; 2017; 1487():269-276. PubMed ID: 27924574
[TBL] [Abstract][Full Text] [Related]
37. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
38. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
[TBL] [Abstract][Full Text] [Related]
39. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
[TBL] [Abstract][Full Text] [Related]
40. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
